USP35 biomarker test for juvenile autoimmune hepatitis
Part of Digestive system, Immune system & allergy clinical trials.
This study looks at a protein called USP35 in liver tissue to help detect a type of cell damage called ferroptosis in children with autoimmune hepatitis. It may lead to better diagnosis and monitoring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 1 day and 18 years old.
- You must have a diagnosis of juvenile autoimmune hepatitis, including cases without the usual blood markers (seronegative).
- Your liver tissue sample must have enough tissue to test.
- You must not have viral hepatitis.
- You must not be older than 18 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at fats (lipids) in the blood of people with autoimmune hepatitis to find patterns that might help diagnose or monitor the disease. It may lead to better ways to manage the condition.
This study follows people with autoimmune hepatitis (a condition where the immune system attacks the liver) and requires key blood test results at diagnosis. It may help doctors better understand this disease and how it progresses in patients in China.
This trial uses MRI scans to look for “biomarkers,” which are measurable signs in the liver, to better understand autoimmune liver diseases in children and teens. It may help doctors track disease and improve care by finding imaging patterns linked to illness.
This study looks at whether children with autoimmune hepatitis (a liver disease where the immune system attacks the liver) also have thyroid problems. It may help doctors understand and manage these related conditions better.
This study uses MRI scans to find “biomarkers,” or imaging clues, that may help predict how autoimmune liver conditions will progress in children and young adults. If you qualify, you may get MRI imaging to see whether it relates to future health outcomes.
This study is for people diagnosed with primary biliary cholangitis or autoimmune hepatitis. It aims to learn more about these autoimmune liver conditions and may help guide better care in the future.
Hear when a new Autoimmune Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.